News

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Age and sickle cell disease genotype predicted individuals with sickle cell retinopathy at risk for proliferative disease.

This interview featured a discussion of Alexis’s team’s findings on the importance of treating patients with skin of color and acne-induced post-inflammatory hyperpigmentation.

The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.

Study results highlight the role of HCV and alcohol use in the growing global disease burden posed by cirrhosis, which is projected to increase over the next 20 years.

Transmasculine patients undergoing GAHT may experience adverse lipid profile changes, unlike transfeminine counterparts, which investigators say is cause for closer monitoring.

Patients with hidradenitis suppurativa had the greatest risk of developing various CVS, with heart failure being the most common one.

A systematic review and meta-analysis of 51 studies suggests elevated Lp(a) can help predict risk of premature atherosclerotic cardiovascular disease.

Within one month of treatment, anti-VEGF therapy improves anatomic and visual outcomes among eyes with stage 3 and 4 proliferative sickle cell retinopathy.

A study showed tildrakizumab treated difficult-to-treat psoriasis areas in patients who failed anti-IL17 treatment.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

The multicenter study examined the presentation and outcomes of patients with cirrhosis-related IgAN and compared clinicopathological profiles with primary IgAN.

The treatment, made up of clindamycin phosphate, adapalene, and benzoyl peroxide, led to clear or almost clear skin among a significant number of individuals with acne.

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

In an interview, King provided an overview of the history of psychedelic research for psychiatric conditions, where we are now, and what hurdles investigators must address.

Boehringer Ingelheim expands access to adalimumab biosimilar adalimumab-adbm through agreement with Quallent Pharmaceuticals,

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

Announced by Sanofi on May 10, 2024, the updated FDA label is based on full results from the pivotal phase 3 XTEND-Kids study.

In this interview segment, Rigotti discussed the way in which cytisinicline can help adults to quit e-cigarettes and the future of her team’s research on this product.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

The SEQUOIA-HCM trial presents aficamten as a promising treatment for symptomatic obstructive hypertrophic cardiomyopathy, showing significant improvements in multiple endpoints.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

This discussion covered the topic of e-cigarette use and its potential treatment with cytisinicline, a plant-based medication which may aid vapers in quitting.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.